Moreover, Tanaka et al. demonstrated that high pretreatment Cyfra21-1, but not CEA levels, closely associated with shorter PFS in EGFR-TKI treated EGFR-mutated NSCLC patients [8]. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.